A Bioengineered MSC-EVs nanoplatform restores VCP-dependent mitophagy and promotes regeneration in steatotic livers via the miR-423-5p/SAA1 axis

Post-hepatectomy liver failure (PHLF) in steatotic livers presents a critical clinical challenge, with mortality rates exceeding 30%, primarily due to defective mitophagy and dysregulated lipid metabolism. Currently, effective targeted therapies remain elusive. Through transcriptomic analysis of partial hepatectomy models, we identified Serum Amyloid A1 (SAA1) as a key pathogenic factor driving regeneration failure in fatty livers. To address this, we developed a bioengineered nanoplatform using mesenchymal stem cell-derived extracellular vesicles (MSC-EVs) enriched with miR-423-5p to counteract SAA1-mediated suppression. These engineered EVs, ‌with a size distribution characteristic of small EVs‌, effectively targeted injured hepatocytes and significantly downregulated SAA1 expression in vivo ( P < 0.0001). Mechanistically, we demonstrated that suppressing SAA1 restores VCP-dependent mitophagy flux, reduces hepatic lipid deposition, and triples Ki67 + hepatocyte proliferation compared to controls. The therapeutic efficacy was further validated in free fatty acid (FFA)-treated primary hepatocytes and primary hepatocyte–derived epithelial organoid (PHLO) models of steatosis. Furthermore, analysis of human tissue microarrays confirmed the clinical relevance of the miR-423-5p/SAA1 axis. This preclinical study establishes a dual-functional engineered-EV platform that leverages SAA1 suppression and metabolic modulation and identifies the miR-423-5p/SAA1/VCP axis as a candidate therapeutic pathway; further dose, safety, manufacturing, and large-animal evaluation is required before clinical translation.

Authors

Institutions

Publication Details

Journal
Journal of Nanobiotechnology
Published
2026-11-21
DOI
https://doi.org/10.1186/s12951-026-05198-0
Primary Topic
Extracellular vesicles in disease
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

A Bioengineered MSC-EVs nanoplatform restores VCP-dependent mitophagy and promotes regeneration in steatotic livers via the miR-423-5p/SAA1 axis

Beng Yang, Yuqi Huang, Charlie C. Xiang, Yingchen Huang et al.
Journal of Nanobiotechnology
Extracellular vesicles in disease
article

A Bioengineered MSC-EVs nanoplatform restores VCP-dependent mitophagy and promotes regeneration in steatotic livers via the miR-423-5p/SAA1 axis

Beng Yang, Yuqi Huang, Charlie C. Xiang, Yingchen Huang, Shengchen Hu, Xiao Xu, Xun Qiu, Ning Zhang, Qiang Wei, Di Lu, Jun Pan, Hanqing Liu, Xinyang Zhong, Yunguo Lei
article en

Abstract

Post-hepatectomy liver failure (PHLF) in steatotic livers presents a critical clinical challenge, with mortality rates exceeding 30%, primarily due to defective mitophagy and dysregulated lipid metabolism. Currently, effective targeted therapies remain elusive. Through transcriptomic analysis of partial hepatectomy models, we identified Serum Amyloid A1 (SAA1) as a key pathogenic factor driving regeneration failure in fatty livers. To address this, we developed a bioengineered nanoplatform using mesenchymal stem cell-derived extracellular vesicles (MSC-EVs) enriched with miR-423-5p to counteract SAA1-mediated suppression. These engineered EVs, ‌with a size distribution characteristic of small EVs‌, effectively targeted injured hepatocytes and significantly downregulated SAA1 expression in vivo ( P < 0.0001). Mechanistically, we demonstrated that suppressing SAA1 restores VCP-dependent mitophagy flux, reduces hepatic lipid deposition, and triples Ki67 + hepatocyte proliferation compared to controls. The therapeutic efficacy was further validated in free fatty acid (FFA)-treated primary hepatocytes and primary hepatocyte–derived epithelial organoid (PHLO) models of steatosis. Furthermore, analysis of human tissue microarrays confirmed the clinical relevance of the miR-423-5p/SAA1 axis. This preclinical study establishes a dual-functional engineered-EV platform that leverages SAA1 suppression and metabolic modulation and identifies the miR-423-5p/SAA1/VCP axis as a candidate therapeutic pathway; further dose, safety, manufacturing, and large-animal evaluation is required before clinical translation.

Journal of Nanobiotechnology
Zhejiang Chinese Medical University (CN), Hangzhou Medical College (CN), Zhejiang University (CN), Nanjing Medical University (CN)
Extracellular vesicles in disease
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon